Related references
Note: Only part of the references are listed.Cetuximab for the treatment of colorectal cancer
Derek J. Jonker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Design of phase II cancer trials using a continuous endpoint of change in tumor size: Application to a study of sorafenib and erlotinib in non-small-cell lung cancer
Theodore G. Karrison et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2007)
Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab
Shirin Khambata-Ford et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Drug therapy: Trastuzumab - Mechanism of action and use in clinical practice
Clifford A. Hudis
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada clinical trials group
Malcolm J. Moore et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
We should desist using RECIST, at least in GIST
Robert S. Benjamin et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
FDA drug approval summary: Bevacizumab plus FOLFOX4 as second-line treatment of colorectal cancer
Martin H. Cohen et al.
ONCOLOGIST (2007)
FDA drug approval summary: Bevacizumab (Avastin (R)) plus carboplatin and paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer
Martin H. Cohen et al.
ONCOLOGIST (2007)
Sorafenib for the treatment of advanced renal cell carcinoma
Robert C. Kane et al.
CLINICAL CANCER RESEARCH (2006)
Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)
N Thatcher et al.
LANCET (2005)
Food and Drug Administration drug approval summary: Temozolomide plus radiation therapy for the treatment of newly diagnosed glioblastoma multiforme
MH Cohen et al.
CLINICAL CANCER RESEARCH (2005)
Epidermal growth factor receptor mutations in non-small-cell lung cancer:: Implications for treatment and tumor biology
PA Jänne et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Approval summary: Docetaxel in combination with prednisone for the treatment of androgen-independent hormone-refractory prostate cancer
R Dagher et al.
CLINICAL CANCER RESEARCH (2004)
The role of erlotinib (Tarceva, OSI 774) in the treatment of non-small cell lung cancer
R Perez-Soler
CLINICAL CANCER RESEARCH (2004)
Phase II study of alternating chemotherapy regimens for advanced non-small cell lung cancer
DJ Stewart et al.
LUNG CANCER (2004)
The cost of institutional review board procedures in Multicenter Observational Research
K Humphreys et al.
ANNALS OF INTERNAL MEDICINE (2003)
The joint modeling of a longitudinal disease progression marker and the failure time process in the presence of cure
NJ Law et al.
BIOSTATISTICS (2002)
ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: Results of a phase I trial
M Ronson et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
New guidelines to evaluate the response to treatment in solid tumors
F Duffaud et al.
BULLETIN DU CANCER (2000)
New guidelines to evaluate the response to treatment in solid Tumors
P Therasse et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)